№ lp_1_2_08192
File format: docx
Character count: 17965
File size: 534 KB
The document provides a clinical protocol for the examination of resection specimens from pediatric patients with Ewing sarcoma, detailing required procedures, specimen handling, and molecular testing requirements.
Year:
2019
Region / city:
Not specified
Theme:
Oncology
Document type:
Clinical Protocol
Authors:
Erin Rudzinski, MD; Bruce Pawel, MD; Armita Bahrami, MD; M. John Hicks, MD
Target audience:
Healthcare professionals involved in pediatric oncology
Period of validity:
Not specified
Approval date:
Not specified
Date of modifications:
February 2019
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Protocol version:
6.0
Date:
18 September 2020
Study name:
rEECur
Study design:
International randomised controlled trial
Medical condition:
Recurrent and primary refractory Ewing sarcoma
Intervention:
Chemotherapy
Sponsor:
University of Birmingham
Sponsor protocol number:
RG_13-277
CRCTU number:
SA2015
EudraCT number:
2014-000259-99
ISRCTN reference number:
ISRCTN36453794
Chief Investigator:
Dr Martin McCabe
Coordinating institution:
Cancer Research UK Clinical Trials Unit, University of Birmingham
Geographic scope:
International
Participating regions:
United Kingdom, Germany, Italy, France, Spain, Scandinavia, Australia, New Zealand, Switzerland
Target population:
Patients with recurrent or primary refractory Ewing sarcoma
Regulatory status:
Ethics and regulatory approval required per participating country
Amendment history:
Substantial amendments between 2014 and 2016
Document type:
Clinical trial protocol
Randomisation method:
Centralised online randomisation
Trial phase:
Phase II (Germany-specific limitation noted)
Year:
2024
Region / City:
Ewing, New Jersey
Theme:
Scholarship Application
Document Type:
Application Form
Organization / Institution:
Ewing Girls Softball Association
Author:
Laura Fresco, President
Target Audience:
Graduating high school students who have participated in the Ewing Girls Softball Association
Period of Validity:
May 3, 2024
Approval Date:
January 31, 2024
Date of Modifications:
Not specified
Year of publication:
2025
Receipt of originals:
10/27/2025
Acceptance for publication:
11/27/2025
DOI:
https://doi.org/10.56238/isevjhv4n6-002
Authors:
Fernanda Cristina Galerani Gualtieri Parpinelli; Augustin Malzac; Henrique Lucas Codognoto; Cristina Jardelino de Lima; Guilherme Banck; Diogo Melo Mendo
Type of document:
Narrative literature review
Field:
Oncology; Orthopedic Oncology
Subject:
Multidisciplinary management of osteosarcoma, chondrosarcoma, and Ewing sarcoma
Population focus:
Pediatric and young patients with primary malignant bone tumors
Study period covered:
2015–2025
Databases consulted:
PubMed; Scopus; Cochrane
Therapeutic approaches discussed:
Surgical resection (R0 margins); Neoadjuvant and adjuvant chemotherapy (MAP; VAC/IE); Radiotherapy; Proton therapy; Immune checkpoint inhibitors; CAR-T cell therapy
Molecular aspects:
EWS-FLI1 translocation; IDH1/IDH2 mutations; Circulating tumor DNA (ctDNA)
Imaging modalities:
MRI; CT; PET-CT
Keywords:
Osteosarcoma; Chondrosarcoma; Ewing Sarcoma; Targeted Therapy; EWS-FLI1; Biomarkers; Immunotherapy
Protocol version:
6.0
Date:
18 September 2020
Study name:
rEECur
Study design:
International randomised controlled trial
Medical condition:
Recurrent and primary refractory Ewing sarcoma
Intervention:
Chemotherapy
Sponsor:
University of Birmingham
Sponsor protocol number:
RG_13-277
CRCTU number:
SA2015
EudraCT number:
2014-000259-99
ISRCTN reference number:
ISRCTN36453794
Chief Investigator:
Dr Martin McCabe
Coordinating institution:
Cancer Research UK Clinical Trials Unit, University of Birmingham
Geographic scope:
International
Participating regions:
United Kingdom, Germany, Italy, France, Spain, Scandinavia, Australia, New Zealand, Switzerland
Target population:
Patients with recurrent or primary refractory Ewing sarcoma
Regulatory status:
Ethics and regulatory approval required per participating country
Amendment history:
Substantial amendments between 2014 and 2016
Document type:
Clinical trial protocol
Randomisation method:
Centralised online randomisation
Trial phase:
Phase II (Germany-specific limitation noted)
Year:
2021
Region / City:
International
Topic:
Soft tissue sarcoma histopathology
Document Type:
Guide
Organization / Institution:
International Collaboration on Cancer Reporting (ICCR)
Author:
Not specified
Target Audience:
Pathologists, oncologists, medical professionals
Effective Period:
Ongoing
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2022
Protocol Version:
4.4.0.0
Protocol Posting Date:
March 2022
Required Use Date:
December 2022
Program:
CAP Laboratory Accreditation Program
Issuing Organization:
College of American Pathologists
Committees:
CAP Cancer Committee; CAP Pathology Electronic Reporting Committees
Authors:
Uma G. Krishnamurti, MD, PhD; Barbara A. Crothers, DO
Subject:
Pathologic examination and synoptic reporting of primary uterine sarcoma resection specimens
Tumor Types Covered:
Leiomyosarcoma; Adenosarcoma; Endometrial stromal sarcoma; Undifferentiated uterine/endometrial sarcoma
Excluded Tumor Types:
Carcinoma; Lymphoma
Applicable Procedures:
Total hysterectomy; Supracervical hysterectomy; Radical hysterectomy; Salpingo-oophorectomy; Omentectomy; Peritoneal biopsy; Peritoneal washing
Reporting Standard:
Synoptic reporting format with core and conditional data elements
Staging Standards Referenced:
AJCC-UICC 8; FIGO Cancer Report 2018
Intended Users:
Pathologists and laboratories participating in CAP accreditation
Year of publication:
2025
Receipt of originals:
10/27/2025
Acceptance for publication:
11/27/2025
DOI:
https://doi.org/10.56238/isevjhv4n6-002
Authors:
Fernanda Cristina Galerani Gualtieri Parpinelli; Augustin Malzac; Henrique Lucas Codognoto; Cristina Jardelino de Lima; Guilherme Banck; Diogo Melo Mendo
Type of document:
Narrative literature review
Field:
Oncology; Orthopedic Oncology
Subject:
Multidisciplinary management of osteosarcoma, chondrosarcoma, and Ewing sarcoma
Population focus:
Pediatric and young patients with primary malignant bone tumors
Study period covered:
2015–2025
Databases consulted:
PubMed; Scopus; Cochrane
Therapeutic approaches discussed:
Surgical resection (R0 margins); Neoadjuvant and adjuvant chemotherapy (MAP; VAC/IE); Radiotherapy; Proton therapy; Immune checkpoint inhibitors; CAR-T cell therapy
Molecular aspects:
EWS-FLI1 translocation; IDH1/IDH2 mutations; Circulating tumor DNA (ctDNA)
Imaging modalities:
MRI; CT; PET-CT
Keywords:
Osteosarcoma; Chondrosarcoma; Ewing Sarcoma; Targeted Therapy; EWS-FLI1; Biomarkers; Immunotherapy
Grant Name:
ANZSA 2023 SRG
Year:
2023
Organization:
ANZSA
Related Organization:
ASSG
Document Type:
Grant Application Form
Subject Area:
Sarcoma Research
Application Components:
Applicant Details, Project Description, Budget, Lay Summary, Supporting Documents
Submission Method:
Email submission
Required Attachments:
Curriculum Vitae; Letters of Recommendation or Support (optional)
Project Duration:
12 months
Contact Email:
[email protected]
Year:
2010–2025
Region / City:
Italy
Topic:
Molecular profiling of mesenchymal tumors
Document type:
Consensus paper supplement
Institution:
Italian Sarcoma Group
Audience:
Medical researchers, oncologists, pathologists
Methods:
Literature review, PubMed search, article screening
Number of articles reviewed:
2,699
Number of articles included in final analysis:
146
Additional publications considered:
December 31, 2024 – August 31, 2025
Filters applied:
Full text, clinical trials, guidelines, meta-analyses, observational studies, humans, English language
Search strategy:
Next-generation sequencing, genomic profiling, liquid biopsy, RNAseq, fusion panel, methylation
Reference list selection:
Most relevant articles according to journal guidelines
Systematic review type:
Consensus-based literature review
Screening process:
Title screening, abstract evaluation, full-text evaluation
Year:
2018
Region:
North America
Subject:
Cancer data collection, Soft tissue sarcoma, GIST, Thymoma
Document type:
Guidelines and Q&A
Organization:
NAACCR, AJCC, SEER, CoC
Author:
Not specified
Target audience:
Cancer registrars, clinical coders, oncology data specialists
Effective period:
Cases diagnosed 2018 onward
Date issued:
January 11, 2018
Related resources:
ICD-O 3 Coding Guidelines, FORDS 2016, SEER 2016 Coding Manual, STORE 2018
Version:
4.4.0.0
Protocol Posting Date:
June 2021
CAP Laboratory Accreditation Program Protocol Required Use Date:
March 2022
Authors:
Patrick L. Fitzgibbons, MD, FCAP; James L. Connolly, MD
Note:
Accreditation Requirements
Year:
2021
Region / City:
Global
Theme:
Oncology, Breast Cancer
Document Type:
Protocol
Organization / Institution:
CAP (College of American Pathologists)
Author:
Patrick L. Fitzgibbons, MD, FCAP; James L. Connolly, MD
Target Audience:
Medical professionals, pathologists
Period of Validity:
From March 2022
Date of Approval:
June 2021
Date of Changes:
June 2021
Year:
2024
Region / City:
Not specified
Subject:
Pathology, Oncology
Document Type:
Protocol
Organization / Institution:
CAP (College of American Pathologists)
Author:
Uma G. Krishnamurti, MD, PhD; Kimberly H. Allison, MD; Patrick L. Fitzgibbons, MD, FCAP; James L. Connolly, MD
Target Audience:
Pathologists, Medical Institutions
Period of Validity:
March 2025
Approval Date:
Not specified
Date of Last Change:
June 2024
Version:
4.2.1.0
Protocol Posting Date:
June 2025
CAP Laboratory Accreditation Program Protocol Required Use Date:
March 2026
Year:
2025
Region / City:
Not specified
Subject:
Renal cell carcinoma, nephrectomy, tumor classification
Document Type:
Protocol
Institution:
CAP (College of American Pathologists)
Author:
Paari Murugan, MD, FCAP*, Robert W. Allan, MD, FCAP*, Lara R. Harik, MD, FCAP*
Target Audience:
Pathologists, medical professionals involved in cancer diagnostics
Effective Period:
March 2026 onward
Approval Date:
June 2025
Revision Date:
Not specified
Year:
2016
Region / City:
Orlando, FL
Theme:
Biomechanics, Orthopaedics
Document Type:
Conference Paper
Organization / Institution:
Orthopaedic Research Society
Authors:
Sueyoshi T, Small SR, Elliot JB, Gibbs GE, Seale RB, Berend ME, Ritter MA
Target Audience:
Medical professionals, researchers in orthopaedics
Period of Activity:
March 5-8, 2016
Date of Approval:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
Southampton, UK
Topic:
Oesophago-gastric cancer, neoadjuvant therapy, cardiopulmonary exercise testing
Document Type:
Research Article
Institution:
University of Southampton, Southampton NIHR Biomedical Research Centre
Author:
Malcolm A West, William CA Baker, Saqib Rahman, Alicia Munro, Sandy Jack, Michael PW Grocott, Timothy J Underwood, Denny ZH Levett
Target Audience:
Medical professionals, oncologists, researchers
Period of Effectiveness:
Not specified
Approval Date:
Not specified
Date of Modifications:
Not specified
Version:
5.1.0.0
Protocol Posting Date:
September 2025
CAP Laboratory Accreditation Program Protocol Required Use Date:
June 2026
Note:
The changes included in this current protocol version affect accreditation requirements. The new deadline for implementing this protocol version is reflected in the above accreditation date.
Resection:
Includes pneumonectomy, lobectomy, segmentectomy, and wedge resection
Carcinoma:
Includes non-small cell carcinoma, small cell carcinoma, and carcinoid tumor of the lung
Year:
2025
Region / City:
Global
Theme:
Medical Protocol, Oncology
Document Type:
Protocol
Institution:
CAP (College of American Pathologists)
Author:
Frank Schneider, MD, Kirtee Raparia, MD, FCAP
Target Audience:
Medical professionals in pathology and oncology
Period of Validity:
2025-2026
Approval Date:
September 2025
Modification Date:
September 2025
Year:
2023
Region:
China
Subject:
Male rectal cancer, laparoscopic surgery, postoperative urogenital function
Document Type:
Clinical trial protocol
Organization:
Sun Yat-sen University, Multiple affiliated hospitals
Author:
Research Team
Target Audience:
Medical professionals, researchers, clinicians
Period of Action:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
Singapore
Theme:
Hepatocellular carcinoma, Surgical resection
Document type:
Meta-analysis
Author:
Aaron JL Lee, Andrew GR Wu, Kuo Chao Yew, Vishal G Shelat
Target audience:
Medical professionals, Researchers
Period of validity:
Not specified
Approval date:
February 1, 2023
Date of changes:
Not specified
Year:
2024
Region / City:
N/A
Topic:
Medical protocol
Document Type:
Protocol
Organization / Institution:
CAP Laboratory Accreditation Program
Authors:
Julie C. Fanburg-Smith, MD, FCAP; Paari Murugan, MD, FCAP; Andrew Horvai, MD, PhD; Fernanda Amary, MD, PhD; Meera Hameed, MD, FCAP; Michael J. Klein, MD.
Target Audience:
Pathologists, medical professionals in oncology
Effective Period:
March 2025
Approval Date:
June 2024
Date of Changes:
June 2024
Year:
2020
Protocol Version:
4.2.0.1
Protocol Posting Date:
February 2020
Required Use Date:
February 2020
Subject:
Primary carcinoma of the vagina
Procedure:
Resection (includes vaginectomy)
Tumor Types Included:
Squamous cell carcinoma, adenocarcinoma and variants, carcinosarcoma, neuroendocrine carcinoma, mixed epithelial–neuroendocrine tumors
Staging System:
pTNM (8th Edition, AJCC Staging Manual), 2018 FIGO Cancer Report
Issuing Organization:
College of American Pathologists
Program:
CAP Laboratory Accreditation Program
Committees:
CAP Cancer Committee; CAP Pathology Electronic Reporting Committee
Authors:
Saeid Movahedi-Lankarani, MD; Uma Krishnamurti, MD, PhD; Debra A. Bell, MD; George G. Birdsong, MD; Charles V. Biscotti, MD; Christopher N. Chapman Jr, MD; Dina H. Kandil, MD; Veronica Klepeis, MD, PhD; Anthony G. Montag, MD; Christopher N. Otis, MD
Document Type:
Cancer protocol and surgical pathology reporting guideline
Applicable Specimens:
Definitive primary cancer resection specimens
Exclusions:
Biopsy specimens; cytologic specimens; lymphoma; sarcoma; recurrent or metastatic tumors resected separately